BMRN

#861
BioMarin Pharmaceuticals Inc
55.47 USD
+1.08%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
55.47
55.47
年范围
50.76
66.28
日变化
+1.08%
每月变动
-2.12%
6个月变化
+5.98%
年变化
-6.96%
前一天收盘价
54.88
开盘价
55.47
买价
卖价
最低价
55.47
High
55.47
交易量
144
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 10.67 B
  • Employee 3 221
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
33.02
市销率
3.64

BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

新闻